Item 7.01 Regulation FD Disclosures

On June 29, 2020, Biomerica, Inc. ("Biomerica") issued a press release announcing that it has signed a definitive agreement with the University of Texas Health Science Center at Houston to join the clinical trial for Biomerica's new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.

The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.




Item 8.01  Other Events

On June 25, 2020, Biomerica, Inc. signed a definitive agreement with the University of Texas Health Science Center at Houston to join the clinical trial for Biomerica's new InFoods® diagnostic-guided therapy designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.




Item 9.01     Financial Statements and Exhibits



(d)  Exhibits





Number      Description



99.1         Press Release issued June 29, 2020.



                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses